Badurdeen Dilhana S, Li Zhen, Lee Jeong-Heon, Ma Tao, Bhagwate Aditya Vijay, Latanich Rachel, Dogiparthi Arjit, Ordog Tamas, Kovbasnjuk Olga, Kumbhari Vivek, Foulke-Abel Jennifer
Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine, and Pathology, and Center for Cell Signaling in Gastroenterology (C-SiG), Mayo Clinic, Rochester, MN 55905, USA.
bioRxiv. 2025 Mar 1:2024.05.06.591758. doi: 10.1101/2024.05.06.591758.
Obesity is an epidemic with myriad health effects, but little is understood regarding individual obese phenotypes and how they may respond to therapy. Epigenetic changes associated with obesity have been detected in blood, liver, pancreas, and adipose tissues. Previous work using human organoids found that dietary glucose hyperabsorption is a steadfast trait in cultures derived from some obese subjects, but detailed transcriptional or epigenomic features of the intestinal epithelia associated with this persistent phenotype are unknown. This study evaluated differentially expressed genes and relative chromatin accessibility in intestinal organoids established from donors classified as non-obese, obese, or obese hyperabsorptive by body mass index and glucose transport assays. Transcriptomic analysis indicated that obese hyperabsorptive subject organoids have significantly upregulated dietary nutrient absorption transcripts and downregulated type I interferon targets. Chromatin accessibility and transcription factor footprinting predicted that enhanced HNF4G binding may promote the obese hyperabsorption phenotype. Quantitative RT-PCR assessment in organoids representing a larger subject cohort suggested that intestinal epithelial expression of CUBN, GIP, SLC5A11, and SLC2A5 were highly correlated with hyperabsorption. Thus, the obese hyperabsorption phenotype was characterized by transcriptional changes that support increased nutrient uptake by intestinal epithelia, potentially driven by differentially accessible chromatin. Recognizing unique intestinal phenotypes in obesity provides a new perspective in considering therapeutic targets and options to manage the disease.
肥胖是一种具有多种健康影响的流行病,但对于个体肥胖表型以及它们对治疗的反应了解甚少。在血液、肝脏、胰腺和脂肪组织中已检测到与肥胖相关的表观遗传变化。先前使用人类类器官的研究发现,饮食葡萄糖高吸收是一些肥胖受试者来源的培养物中的一个稳定特征,但与这种持续表型相关的肠上皮细胞的详细转录或表观基因组特征尚不清楚。本研究评估了通过体重指数和葡萄糖转运测定分类为非肥胖、肥胖或肥胖高吸收的供体建立的肠类器官中差异表达的基因和相对染色质可及性。转录组分析表明,肥胖高吸收受试者的类器官中饮食营养吸收转录本显著上调,I型干扰素靶点下调。染色质可及性和转录因子足迹预测,增强的HNF4G结合可能促进肥胖高吸收表型。对代表更大受试者队列的类器官进行的定量RT-PCR评估表明,CUBN、GIP、SLC5A11和SLC2A5的肠上皮表达与高吸收高度相关。因此,肥胖高吸收表型的特征是转录变化,支持肠上皮细胞增加营养摄取,这可能由差异可及的染色质驱动。认识到肥胖中独特的肠道表型为考虑治疗靶点和管理该疾病的选择提供了新的视角。